Cell Therapies commences negotiations with Novartis to manufacture life-changing CAR T-cell treatments at Peter MacCallum Cancer Centre for young people with blood cancer

April 16th, 2019 | Posted by webmaster in News - (Comments Off on Cell Therapies commences negotiations with Novartis to manufacture life-changing CAR T-cell treatments at Peter MacCallum Cancer Centre for young people with blood cancer)

Melbourne’s Cell Therapies is set to become a global hub for the manufacture of cutting-edge CAR T-cell therapy to treat children and young adults with aggressive blood cancer.

Federal Health Minister Greg Hunt on Monday announced the government will reimburse Kymriah® (tisagenlecleucel, formerly CTL019) following an approval from the Medical Services Advisory Committee (MSAC).

Kymriah is an immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient’s own T-cells, genetically reengineered and programmed to recognise and kill cancer cells.

Today’s announcement funds Kymriah for paediatric and young adult patients up to 25 with B-cell precursor acute lymphoblastic leukaemia (ALL) who relapse or do not respond to initial therapy.

This follows a recent $105 million announcement from the Australian Government and Peter Mac which will more than double the Cell Therapies current manufacturing footprint.

“We are delighted by Novartis’ announcement and we look forward to the next stage of our relationship with them,” Chief Scientific Officer of Cell Therapies A/Prof Dominic Wall said.

“This new high-throughput facility will allow an increased production to 1,000 patient doses per year, up from around 50 currently”

“This in turn will create over 50 new highly skilled manufacturing jobs and means we have the ability to supply cell products across Australia and the region.
Kymriah is the only chimeric antigen receptor T-cell therapy approved by the Therapeutic Goods Administration in Australia”

About Cell Therapies Pty Ltd

Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in the Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for regional deployment of cellular therapies for our clients. We have TGA licences that allow us to safely manufacture and supply these CAR-T therapies to patients in Australia.

 

Open House for ISCT 2019

February 21st, 2019 | Posted by webmaster in News - (Comments Off on Open House for ISCT 2019)

Cell Therapies Pty Ltd will be holding an Open House on Tuesday, 28 May 2019 at 17:30 in conjunction with the 2019 International Society for Cell and Gene Therapy (ISCT) Annual Meeting, which will be held in Melbourne, Australia from 29 May – 01 June.  The Open House will be held at the Peter MacCallum Cancer Centre, 7th floor, 305 Grattan Street, Melbourne, and will consist of a short lecture followed by a drinks and hors d’oeuvres networking reception prior to tours being conducted of the Cell Therapies GMP clean room facility.  For more information, please see our invitation Cell Therapies Open House Invitation or visit the ISCT website Pre-Meeting GMP Facility Tours

To register, please email ISCT2019OpenHouse@celltherapies.com.au.”

New cancer treatment approved in Australia

December 19th, 2018 | Posted by webmaster in News - (Comments Off on New cancer treatment approved in Australia)

(19 Dec 18) Novartis Australia has announced the TGA approval of Kymriah® (tisagenlecleucel), for the treatment of two types of aggressive cancers. This one-time treatment is called “CAR-T” cellular therapy, and it is manufactured individually for each patient, using the patient’s own immune system cells.

Kymriah® is approved in Australia for the treatment of relapsed or refractory patients with paediatric B-cell acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL).

We congratulate Novartis on this significant achievement which will bring a life changing treatments to patients in need.

A new video explains the elegant way that CAR-T treatment works!

December 19th, 2018 | Posted by webmaster in News - (Comments Off on A new video explains the elegant way that CAR-T treatment works!)

To view the video, click here

Dr Dawn Driscoll appointed as CEO at Cell Therapies Pty Ltd

October 4th, 2017 | Posted by webmaster in News - (Comments Off on Dr Dawn Driscoll appointed as CEO at Cell Therapies Pty Ltd)

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Dawn Driscoll as its new Chief Executive Officer.

Dawn is highly experienced in the cellular therapy industry and has over 20 years experience in the biotechnology industry globally, with expertise in cell therapy, licensing, acquisitions and commercialisation.

The Board of Cell Therapies and Peter Mac as the majority shareholder is very pleased to have Dawn join and lead our team.

Our company is in good shape and in a great position to lead the Asia-Pacific market in this exciting time as new CAR-T cell therapies and other immunotherapies come to market. Our unique offering in lab-to-benchside cellular vaccine development, manufacture and clinical treatment within a hospital and academic research institute sets us apart from our competitors. We have a track record of novel and first-in human trials rapidly delivered to the highest grade GMP.

The Board would also like to thank Dr Dominic Wall for his leadership during this transition period.

A/Prof Leslie Reti
Chairman of Cell Therapies Pty Ltd Board of Directors

CTPL awarded Australian Global Innovation Linkages programme grant

June 26th, 2017 | Posted by webmaster in News - (Comments Off on CTPL awarded Australian Global Innovation Linkages programme grant)

Melbourne, Australia 26 June 2017: Cell Therapies has been awarded $1,000,000 in funding by the Australian Government Department of Industry, Innovation and Science through the Global Innovation Linkages programme.  On 10 April 2017, CTPL was announced as one of the nine successful Australian businesses and research organisations to be granted Round 1 funding to collaborate with global partners in science, research and development projects.

Cell Therapies was the lead applicant for the grant, forging a collaboration with 5 other organisations from Australia and the United States, to translate the development of an innovative dual-imaging cell tracking agent into cancer immunotherapy clinical studies as the next step towards commercialisation.

About Global Innovation Linkages Programme 

The Global Innovation Linkages programme provides funding to help Australian businesses and researchers to collaborate with global partners on strategically focused, leading-edge research and development projects.  More information about the Global Innovation Linkages programme is available at https://www.business.gov.au/assistance/global-innovation-linkages-programme.

About Cell Therapies Pty Ltd

Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for Asian deployment of cellular therapies for our clients.

CTPL receives APAC Bioprocessing Excellence Award

February 20th, 2017 | Posted by webmaster in News - (Comments Off on CTPL receives APAC Bioprocessing Excellence Award)

Melbourne, Australia 20 February 2017: Cell Therapies commitment to, and excellence in, bringing innovative cellular therapies into clinical practise has been recognised with an IMAPAC Asia-Pacific Bioprocessing Excellence Award. Managing Director and  CEO Dr Tim Oldham accepted the award for “Best Bioprocessing Excellence in Australia (CMO Category)” at an awards ceremony in Singapore on 15 February.

“It is an honour to receive this award on behalf of our talented and committed team” said Dr Oldham after the ceremony. “This award recognizes both the critical role that specialized manufacturing and supply chain capabilities will play in ensuring patient access to innovative cell and gene therapies that can transform health outcomes, and confirms Cell Therapies’ leadership in the field in Asia Pacific”.

About APAC Bioprocessing Excellence Awards 

APAC Bioprocessing Excellence Awards aim to recognize outstanding bioprocessing people, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and bets practices in manufacturing, Asia’s Bioprocessing Excellence Awards aim to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow.

About Cell Therapies Pty Ltd

Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia and PharmaBio Corp in Japan, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for Asian deployment of cellular therapies for our clients.

CTPL CEO, Tim Oldham, elected to Alliance for Regenerative Medicine 2017 Board of Directors

October 26th, 2016 | Posted by webmaster in News - (Comments Off on CTPL CEO, Tim Oldham, elected to Alliance for Regenerative Medicine 2017 Board of Directors)

Melbourne, Australia, 11 October 2016: Cell Therapies Pty Ltd (CTPL) is pleased to announce that CEO and Managing Director Dr Tim Oldham has been elected to the Board of the Alliance for Regenerative Medicine (ARM) for 2017.

AusBiotech CEO Glenn Cross said: “On behalf of the Regenerative Medicine Advisory Group (RMAG) and AusBiotech, I would like to congratulate Tim Oldham on being elected to the Alliance for Regenerative Medicine 2017 Board of Directors. This is a prestigious position in an important and promising area of Australian medicine. Dr Oldham is a valuable member of the RMAG, and we look forward to working with Dr Oldham on future projects.”

ARM is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. By leveraging the expertise of its membership, ARM empowers multiple stakeholders to promote legislative, regulatory and public understanding of, and support for, this expanding field. Based in Washington, DC, ARM promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare.

“ARM leadership reflects the geographical and technological diversity of our membership,” said Morrie Ruffin, managing director of ARM in ARM’s announcement of the 2017 leadership. “We welcome these new slates of officers, directors and executive committee members; each has demonstrated direct involvement and active participation in ARM’s activities and has made vital contributions to the advancement of this sector.”

“I look forward to continuing CTPL’s significant contribution to our industry through this appointment, and in particular to increasing the voice and profile of AusBiotech’s Regenerative Medicine Advisory Group and the Australian industry in general” said Dr Oldham.

http://alliancerm.org/press/alliance-regenerative-medicine-announces-election-2017-arm-officers%2C-executive-committee-and

 

ISCT 2016

August 19th, 2016 | Posted by webmaster in News | Uncategorized - (Comments Off on ISCT 2016)

CT’s contribution to ISCT 2016

Representatives from Cell Therapies presented at ISCT Singapore on the following topics:

Apheresis – Douglas Watson, Cell Therapy Specialist

Initial Comparison of 3 apheresis platforms for supporting the collection of CD3+ cells for CAR-T production

Flow Cytometry – Alex Rizzitelli, Cell Therapy Specialist

Flow cytometry tools for characterisation of GMP cell products

COGS Optimisation – Tim Oldham, CEO

COGS by Design – A systems approach to achieving commercially viable cellular therapy products

Australian Cell Therapy Landscape – Tim Oldham, CEO

Advantage Australia – A Stepping stone to Asian and global development of cellular therapies

Apheresis for cellular therapy manufacturing: need for improved collection data

February 8th, 2016 | Posted by webmaster in News - (Comments Off on Apheresis for cellular therapy manufacturing: need for improved collection data)

Melbourne 8 Feb 2016: Cell collection via apheresis is the starting point for manufacture of many cellular therapies, including most immuno-therapies. The high patient-to-patient variability, coupled with the specialised skills needed for these collections mean manufacturers have to deal with significant variation in incoming cellular material. Manufacturers are only now coming to grips with the implications of this variation, let alone how to manage and control it. Cell Therapies Pty Ltd CEO Tim Oldham discussed the importance of understanding apheresis variability and approaches to managing and controlling it at the recent Cell & Gene Therapy Leaders Forum in Washington DC (see the presentation Managing apheresis as source of cellular therapy starting material) and Alexey Bersenev has followed up with a useful blog at Stem Cell Assays (http://stemcellassays.com/2016/01/standardization-of-apheresis-collections-for-cell-product-manufacturing/#comments). Dr Oldham argued that collating collection data across many centres and collections to enable apheresis variability to be characterized and understood, and to benchmark individual site, operator and collection performance would be an invaluable tool to aid manufacturing process development.